A5089235307- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Statistical Methods in Clinical Trials
- Biosimilars and Bioanalytical Methods
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Hepatitis C virus research
- Mathematical Biology Tumor Growth
- Attention Deficit Hyperactivity Disorder
- Child and Adolescent Psychosocial and Emotional Development
- Hepatitis B Virus Studies
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Maternal Mental Health During Pregnancy and Postpartum
- Biofield Effects and Biophysics
- Liver Disease Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Radiomics and Machine Learning in Medical Imaging
- Mental Health Research Topics
- HER2/EGFR in Cancer Research
- Machine Learning in Healthcare
- Bioinformatics and Genomic Networks
- Multiple and Secondary Primary Cancers
Queen Mary Hospital
1977-2024
Weatherford College
2023
Roche (United States)
2020-2022
Bristol-Myers Squibb (United States)
2014-2018
Queen Mary University of London
2015
King's College School
2013
King's College London
2013
United States Military Academy
2013
University of Hong Kong
1983
Objective To assess the potential association between prenatal use of antidepressants and risk attention-deficit/hyperactivity disorder (ADHD) in offspring.Design Population based cohort study.Setting Data from Hong Kong population electronic medical records on Clinical Analysis Reporting System.Participants 190 618 children born public hospitals January 2001 December 2009 followed-up to 2015.Main outcome measure Hazard ratio maternal antidepressant during pregnancy ADHD aged 6 14 years,...
Atezolizumab intravenous (IV) is approved for the treatment of various solid tumours. To improve convenience and health care efficiencies, a coformulation atezolizumab recombinant human hyaluronidase PH20 was developed subcutaneous (SC) use. Part 2 IMscin001 (NCT03735121) randomised phase III, open-label, multicentre, noninferiority study comparing drug exposure SC with IV.
Abstract Baseline patient characteristics and prognostic factors are important considerations in oncology when evaluating the impact of immunogenicity on pharmacokinetics (PK) efficacy. Here, we assessed anti‐drug antibodies (ADA) PK immune checkpoint inhibitor atezolizumab (an anti–PD‐L1 monoclonal antibody). We evaluated data from ≈ 4500 patients 12 clinical trials across different tumor types, treatment settings, dosing regimens. In our dataset, ~ 30% (range, 13–54%) developed...
Purpose: Model-based tumor growth inhibition (TGI) metrics are increasingly incorporated into go/no-go decisions in early clinical studies. To apply this methodology to new investigational combinations requires independent evaluation of TGI recently completed Phase III trials effective immunotherapy. Patients and Methods: Data were extracted from IMpower150, a positive, randomized, study first-line therapy 1,202 patients with non–small cell lung cancer. We resampled baseline characteristics...
Introduction/Objectives: IPSOS (NCT03191786) is a Phase III trial that compared atezolizumab (atezo) monotherapy (mono) vs. single-agent chemotherapy (chemo) (gemcitabine or vinorelbine) in patients with treatment-naïve locally advanced metastatic NSCLC deemed unsuitable for platinum-doublet chemo. The study demonstrated significant OS improvement the atezo arm to chemo vinorelbine); stratified HR of 0.78 (95% CI: 0.63, 0.97; p-value 0.028) [1]. control only allowed gemcitabine vinorelbine,...
The relative merits of proximal gastric vagotomy (PGV), truncal with drainage (TV + D), and antrectomy A) in the treatment chronic duodenal ulcer were evaluated compared 152 patients a prospective, randomized controlled clinical trial. One death occurred after TV A, resulting an operative mortality 2% gastrectomy 0.7% for entire series. After one to six years, stomal ulcers proven by endoscopy eight PGV (16%) D (11.8%); difference was not statistically significant (p > 0.5). additional...
Specialist services for the treatment of attention deficit hyperactivity disorder (ADHD) in adulthood Hong Kong are yet to be developed. This study aims explore experiences adolescents and young adults with ADHD accessing services, coping ADHD-related impairment, their expectations future Kong. Qualitative interviews were conducted a semi-structured guide. Forty adult patients aged between 16 23 included study. The interview recordings transcribed verbatim anonymised. Data analysed thematic...
ABSTRACT IMscin001 is a two‐part dose‐finding (Phase Ib) and ‐confirmation III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients locally advanced or metastatic non‐small cell lung cancer (NSCLC). The objectives the current analyses were characterize population (popPK) determine relationship between exposure safety efficacy endpoints IMscin001. A previously validated IV popPK model was extended add SC absorption...
OBJECTIVES: Fenebrutinib (FEN) is a potent orally administered CNS penetrant Bruton's tyrosine kinase inhibitor that highly selective and noncovalent, leading to reversible binding [1]. FEN inhibits both B-cell proliferation microglia activation are drivers of acute chronic inflammation in relapsing multiple sclerosis (RMS) [2]. FENopta study (NCT05119569) Phase 2 evaluating the efficacy, safety, pharmacokinetics (PK) patients with RMS receiving 200 mg twice-a-day oral fenebrutinib or...
Background: Alectinib (Alecensa) is a tyrosine kinase inhibitor that targets anaplastic lymphoma (ALK) by inhibiting intracellular signaling pathways involved in tumor cell proliferation and survival. was previously approved globally for the treatment of metastatic ALK-positive non-small-cell lung cancer (NSCLC). On April 18, 2024, alectinib United States as adjuvant adult patients following resection NSCLC (tumors ≥ 4 cm or node positive) based on results ALINA study: Phase 3, global,...
Abstract Intravenous (IV) atezolizumab is approved for non–small cell lung and other cancers. Subcutaneous (SC) coformulated with recombinant human hyaluronidase, a permeation enhancer SC dispersion absorption, being developed to improve treatment options, reduce burden, increase efficiency patients practitioners. IMscin001 (NCT03735121), 2‐part, open‐label, global, multicenter, phase 1b/3 study, evaluating the pharmacokinetics (PK), safety, efficacy of atezolizumab. The part 1 (phase 1b)...
We assess the longitudinal tumor growth inhibition (TGI) metrics and overall survival (OS) predictions applied to patients with advanced biliary tract cancer (BTC) enrolled in IMbrave151 a multicenter randomized phase II, double-blind, placebo-controlled trial evaluating efficacy safety of atezolizumab or without bevacizumab combination cisplatin plus gemcitabine. Tumor rate (KG) was estimated for IMbrave151. A pre-existing TGI-OS model hepatocellular carcinoma IMbrave150 modified include...
GDC-0334 is a novel small molecule inhibitor of transient receptor potential cation channel member A1 (TRPA1), promising therapeutic target for many nervous system and respiratory diseases. The pharmacokinetic (PK) profile pharmacodynamic (PD) effects were evaluated in this first-in-human (FIH) study. A starting single dose 25 mg was selected based on integrated preclinical PK, PD, toxicology data following oral administration guinea pigs, rats, dogs, monkeys. Human PK PK-PD characterized...
Phase 1b GO30140 and phase 3 IMbrave150 studies evaluated first-line atezolizumab + bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we pharmacokinetics (PK) safety by hepatic impairment status geographic region.Patients received 1,200 mg 15 mg/kg IV every weeks. Drug concentrations were descriptive statistics population PK. PK adverse event frequencies region.323 patients 162 evaluable. Compared with who had normal function per the National Cancer Institute Organ...
Importance The use of evidence-based standardized outcome measures is increasingly recognized as key to guiding clinical decision-making in mental health. Implementation these into practice has been hampered by lack clarity on what measure and how do this a reliable way. Objective To develop core set for specific neurodevelopmental disorders (NDDs), such attention-deficit/hyperactivity disorder (ADHD), communication disorders, learning motor that may be used across range geographic cultural...
In order to determine the risk of bacteraemia from ERCP, we cultured blood specimens 83 patients before, during and 15 min, 1, 6, 12 24 hours after examination as well in subsequent week whenever fever occurred. No was found 20 who had duodenoscopy only, i.e. whom ERCP failed. Of with normal biliary and/or pancreatic ducts positive culture obtained one patient inadvertent multiple injections contrast material into duct resulted occurrence a pyelogram. Four cultures were amongst 43 an...
The 6-minute walk test (6MWT) is used as a clinical endpoint to evaluate drug efficacy in Duchenne Muscular Dystrophy (DMD) trials. A model was developed using digitized 6MWT data that estimated two slopes and intercepts characterize improvement during development decline. Mean baseline 362 (±87) meters. predicted an at rate of 20 meters/year (95% confidence interval (CI) = 9.4-30) up until 10 years old CI 6.78-13.1), then decline 85 72-98). Interpatient slope variability for were similar...
Abstract Background The goal of this study was to investigate treatment outcome and related intervention processes mindfulness-based cognitive therapy versus health qigong-based waitlist control among individuals with mood disorders. Methods A total 187 disorders were randomized allocated into therapy, or groups. All participants assessed at three time points regard depressive anxiety symptoms, physical mental status, perceived stress, sleep quality, self-efficacy. Linear mixed models...
Abstract Purpose Fenebrutinib (GDC-0853), a Bruton’s tyrosine kinase (BTK) inhibitor was investigated in Phase 2 clinical trial patients with rheumatoid arthritis (RA). Our aim to apply model-informed drug development (MIDD) approach examine the totality of available efficacy data. Methods Population pharmacokinetics (popPK) modeling, exposure-response (E-R) analysis, and model-based meta-analysis (MBMA) fenebrutinib were performed based on Results PopPK after oral administration described...